文献速递炎症性肠病消化内镜

肠道超声表现及其在早期克罗恩病中的预后价值:哥本哈根炎症性肠病队列研究

Intestinal Ultrasound Findings and Their Prognostic Value in Early Crohn's Disease: A Copenhagen IBD Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-03-11

该前瞻性人群队列纳入201例新诊断成人起病克罗恩病患者,在诊断时及随访中行肠道超声并联合症状、生化和内镜评估。3个月时38%达透壁缓解,与无激素临床缓解及较低治疗升级风险相关;基线回盲部IBUS-SAS可预测1年内回盲部切除。

要点

  • 3个月透壁缓解者26% vs 未缓解者53%需治疗升级(P = .003)。
  • 12个月时41%患者达透壁缓解;超重和肥胖降低12个月透壁缓解几率。
  • 基线回盲部IBUS-SAS预测1年内回盲部切除,阈值63,AUC 0.92。

核心结论

  • 透壁缓解是新诊断克罗恩病患者可实现的目标,并与良好临床结局相关,包括持续无激素临床缓解。
  • 诊断时肠道超声表现可预测未来回盲部切除。

研究设计与样本

  • 前瞻性、人群为基础的队列研究,纳入201例新诊断成人起病克罗恩病患者,随访中行肠道超声并联合症状、生化和内镜评估。

主要发现

  • 诊断时超声炎症与诊断延迟无关联。
  • 3个月时38%患者达透壁缓解,结肠病变患者更常达透壁缓解。
  • 3个月透壁缓解与3个月及第一年内所有后续随访的无激素临床缓解显著相关。
  • 透壁缓解与随访至12个月较低治疗升级风险相关(26% vs 53%;P = .003)。
  • 12个月时41%患者达透壁缓解;较高基线体重指数显著降低12个月透壁缓解可能性(超重:OR 0.34;95%CI 0.12-0.94;肥胖:OR 0.16;95%CI 0.04-0.73)。

关键数值与推荐

  • 诊断时回盲部IBUS-SAS是1年内回盲部切除的最佳预测指标,最佳阈值63(AUC 0.92;敏感性100%;特异性73%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We characterize the sonographic features of Crohn's disease at diagnosis and evaluate the prognostic value of intestinal ultrasound during the early stage of disease. METHODS: A prospective, population-based cohort of patients with newly diagnosed Crohn's disease were followed with intestinal ultrasound in conjunction with symptomatic, biochemical, and endoscopic evaluations. RESULTS: Between May 2021 and April 2023, 201 patients with adult-onset Crohn's disease were recruited. No associations were found between sonographic inflammation at diagnosis and diagnostic delay. After 3 months, transmural remission was achieved in 38% of patients, with patients with colonic disease achieving transmural remission more often. Transmural remission at 3 months was significantly associated with steroid-free clinical remission at 3 months and all subsequent follow-ups within the first year. Transmural remission was also associated with a lower risk of treatment escalation during follow-up until 12 months (26% vs 53%; P = .003). At 12 months, 41% had achieved transmural remission. Higher baseline body mass index negatively impacted the likelihood of 12-month transmural remission significantly (overweight: odds ratio [OR], 0.34; 95% confidence interval [CI],0.12-0.94; obese: OR, 0.16; 95% CI, 0.04-0.73). The International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) in the terminal ileum at diagnosis was the best predictor of ileocecal resection during the first year, with an optimal threshold of 63 (area under the curve [AUC], 0.92; sensitivity, 100%; specificity, 73%). CONCLUSIONS: Transmural remission is an achievable outcome target for many patients with newly diagnosed Crohn's disease and is associated with a favorable clinical outcome, including sustained steroid-free clinical remission. Further, intestinal ultrasound findings at diagnosis predict future ileocecal resection.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Madsen GR, Attauabi M, Ilvemark JFKF, et al. Intestinal Ultrasound Findings and Their Prognostic Value in Early Crohn's Disease: A Copenhagen IBD Cohort Study. Clin Gastroenterol Hepatol. 2025. PMID: 40081637. doi:10.1016/j.cgh.2024.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。